BMS Breaks Clinical Losing Streak with Positive Phase 3 Myeloma Readout for Iberdomide
Bristol Myers Squibb (BMS) announced that its investigational drug iberdomide achieved a statistically significant improvement in minimal residual disease (MRD) negativity rates in the Phase 3 EXCALIBER-RRMM study among patients with relapsed or refractory multiple myeloma123579.
Iberdomide was evaluated in combination with daratumumab and dexamethasone versus a standard regimen, demonstrating its efficacy as part of a novel treatment class referred to as CELMoDs (cereblon E3 ligase modulators)135.
This interim success marks a reversal in BMS's recent string of clinical trial disappointments in 2025, providing renewed optimism for the company and its investors9.
The EXCALIBER-RRMM trial will continue to assess the co-primary endpoint of progression-free survival (PFS) and key secondary endpoints such as overall survival and safety, which will be necessary for regulatory approval135.
Iberdomide is positioned as a next-generation targeted protein degradation therapy, following BMS’s blockbuster drugs Revlimid and Pomalyst, but regulatory submission is anticipated only if further endpoints are met3.
Safety data from the iberdomide combination remain consistent with previous studies, supporting its further clinical evaluation1.
Sources:
1. https://www.clinicaltrialsarena.com/news/bms-to-speak-with-regulators-on-mid-stage-multiple-myeloma-success/
2. https://insights.citeline.com/scrip/therapeutic-category/anticancer/bmss-iberdomide-scores-first-major-phase-iii-win-ZDULS6CITVFUDIDUBXANOQZZOU/
3. https://www.biopharmadive.com/news/bristol-myers-iberdomide-multiple-myeloma-study-results-excaliber/760845/
5. https://trial.medpath.com/news/44df0197ef5b3ab6/bristol-myers-squibb-s-iberdomide-combination-achieves-primary-endpoint-in-phase-3-multiple-myeloma-trial
7. https://www.empr.com/news/iberdomide-shows-promising-phase-3-results-in-r-r-multiple-myeloma/